Seelos Therapeutics, Inc. (SEEL)
Company Info
| ISIN | US81577F1093 |
|---|---|
| CUSIP | 81577F109 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $4.45M |
|---|---|
| EPS | -$7.73 |
| Revenue (TTM) | $2.20M |
| Gross Profit (TTM) | -$46.65M |
| EBITDA (TTM) | -$27.71M |
| Year Range | $0.26 - $49.80 |
| Target Price | $120.00 |
| Short % | 6.37% |
| Short Ratio | 2.53 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: SEEL vs. CMPS, SEEL vs. GHRS, SEEL vs. PFE
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Seelos Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Seelos Therapeutics, Inc. had a return of -80.21% year-to-date (YTD) and -98.92% in the last 12 months. Over the past 10 years, Seelos Therapeutics, Inc. had an annualized return of -67.45%, while the S&P 500 had an annualized return of 10.79%, indicating that Seelos Therapeutics, Inc. did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -80.21% | 9.47% |
| 1 month | -40.47% | 1.91% |
| 6 months | -92.57% | 18.36% |
| 1 year | -98.92% | 26.61% |
| 5 years (annualized) | -68.25% | 12.90% |
| 10 years (annualized) | -67.45% | 10.79% |
Monthly Returns
The table below presents the monthly returns of SEEL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -26.62% | 26.47% | -54.19% | -52.79% | -80.21% | ||||||||
| 2023 | 19.60% | -2.72% | -12.51% | -0.16% | 34.95% | 28.32% | 28.03% | -28.76% | -83.12% | 0.92% | -77.38% | 10.32% | -93.18% |
| 2022 | -30.06% | -7.02% | -20.96% | -26.00% | 4.60% | 4.90% | 23.50% | 34.49% | -8.85% | -15.59% | -5.84% | -17.05% | -58.34% |
| 2021 | 36.71% | 37.50% | 68.01% | 22.04% | -49.43% | -14.29% | -14.77% | -2.22% | 9.55% | -10.37% | -19.91% | -5.78% | 3.16% |
| 2020 | -22.39% | -15.67% | -44.07% | 44.75% | 73.24% | -17.89% | 14.85% | -21.53% | 2.94% | -21.02% | 32.43% | 61.22% | 17.91% |
| 2019 | -21.88% | -58.89% | 81.62% | -10.42% | -20.60% | -8.37% | -20.09% | -22.86% | -32.00% | -1.91% | -4.49% | 55.80% | -76.74% |
| 2018 | 24.46% | -59.83% | -55.85% | -33.59% | 3.82% | 39.29% | -23.08% | 10.00% | -6.03% | 9.32% | -9.73% | -37.25% | -89.57% |
| 2017 | 86.92% | 19.34% | -27.24% | -46.45% | -19.17% | 23.71% | 21.24% | 18.98% | 4.91% | -2.34% | -5.39% | 16.46% | 41.54% |
| 2016 | 12.12% | -5.41% | -44.67% | -8.16% | -18.48% | -8.16% | -22.78% | 13.71% | -3.56% | -40.59% | -29.35% | -8.45% | -86.87% |
| 2015 | 39.00% | 58.27% | -15.00% | -14.44% | 4.38% | 2.40% | -15.79% | 18.06% | -14.12% | -9.59% | -17.42% | -9.17% | -1.00% |
| 2014 | -12.08% | -0.00% | -7.73% | 3.02% | 5.19% | -3.43% | -15.56% | -0.00% | -20.53% | -1.99% | -20.27% | -15.25% | -62.26% |
| 2013 | 32.66% | 1.14% | 0.37% | 0.37% | 2.23% | -14.55% | -5.53% | -11.71% | 6.63% | -7.66% | 2.54% | 33.91% | 33.17% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of SEEL is 6, indicating that it is in the bottom 6% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
SEEL (Seelos Therapeutics, Inc.)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Seelos Therapeutics, Inc. (SEEL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Seelos Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Seelos Therapeutics, Inc. was 100.00%, occurring on May 10, 2024. The portfolio has not yet recovered.
The current Seelos Therapeutics, Inc. drawdown is 100.00%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -100% | Feb 28, 2001 | 5833 | May 10, 2024 | — | — | — |
| -90% | Oct 27, 1994 | 1 | Oct 27, 1994 | 2 | Dec 5, 1995 | 3 |
| -78.1% | Jun 23, 1998 | 217 | Jun 28, 1999 | 77 | Oct 20, 1999 | 294 |
| -75% | Jul 9, 1996 | 84 | Aug 19, 1997 | 137 | May 15, 1998 | 221 |
| -37.5% | May 2, 1994 | 2 | May 5, 1994 | 1 | May 12, 1994 | 3 |
Volatility
Volatility Chart
The current Seelos Therapeutics, Inc. volatility is 27.14%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
| Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
| Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |